Business

4basebio Introduces New Branding to Reflect Next Phase of Growth Enabling Development of Advanced Genetic Therapies

CAMBRIDGE, England, July 01, 2025--4basebio PLC (AIM: 4BB) ("4basebio"), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, today announced refreshed branding and the launch of its new website, reflecting the company’s continued growth and success in this rapidly advancing field.

article4basebio PlcJuly 1, 20251/company/4basebio-uk-societas/news/4basebio-introduces-new-branding-to-reflect-next-phase-of-growth-enabling-development-of-advanced-genetic-therapies
4basebio Introduces New Branding to Reflect Next Phase of Growth Enabling Development of Advanced Genetic Therapies

About this update from 4basebio Plc

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":899,"height":283,"url":"https://media.zenfs.com/en/business-wire.com/d60892a39f7e6a95e3cfaa1fbe106ad4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/O6BTrMBCRW_h0KW0jr6eYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d60892a39f7e6a95e3cfaa1fbe106ad4","width":899,"height":283},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/XQfN2jTKUWTwSoPiHwm_Eg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE3OTg7aD01NjY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d60892a39f7e6a95e3cfaa1fbe106ad4","width":899,"height":283}},"lazy":false},{"type":"text","content":"Expanding capabilities in delivering scalable, high-quality synthetic DNA solutions to the global market","length":104,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, England, July 01, 2025--(BUSINESS WIRE)--4basebio PLC (AIM: 4BB) ("4basebio"), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, today announced refreshed branding and the launch of its new website, reflecting the company’s continued growth and success in this rapidly advancing field.","length":352,"tagName":"p"},{"type":"text","content":"Since completing its £40 million investment in November 2024, 4basebio has achieved several major milestones in its mission to deliver scalable, high-quality synthetic DNA solutions to the global market. Notably, in April this year, the Company received MHRA GMP certification for the manufacture and supply of synthetic DNA for clinical use1.","length":343,"tagName":"p"},{"type":"text","content":"The updated brand identity introduces a refined visual system, including a modernised logo, refreshed colour palette, and a suite of new imagery. The Company’s redesigned website provides a more intuitive access point for partners and customers, providing detailed information and support for 4basebio’s expanding capabilities across synthetic DNA, mRNA, gene editing, and plasmid-free manufacturing. With a newly curated content hub, users can also access a range of specialist resources, including data, whitepapers, articles, case studies and more.","length":551,"tagName":"p"},{"type":"text","content":""This brand refresh marks an excitin...

More updates from 4basebio Plc

synthetic DNABUSINESS WIREGMP certificationMHRA